OGEN Key Statistics, Chart & Performance
The current stock price of OGEN is 0.8587 USD. In the past month the price decreased by -7.62%. In the past year, price decreased by -89.84%.
OGEN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.17 | 387.04B | ||
| AMGN | AMGEN INC | 14.77 | 173.92B | ||
| GILD | GILEAD SCIENCES INC | 14.86 | 151.01B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.19 | 115.37B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 79.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 722.43 | 48.67B | ||
| INSM | INSMED INC | N/A | 34.65B | ||
| NTRA | NATERA INC | N/A | 32.38B | ||
| BIIB | BIOGEN INC | 10.78 | 26.47B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.99B | ||
| INCY | INCYTE CORP | 16.37 | 20.64B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.02 | 20.48B |
Related stock screener links
About OGEN
Company Profile
Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. The company is headquartered in Sarasota, Florida and currently employs 3 full-time employees. The company went IPO on 2003-07-09. The company is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The company is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.
Company Info
ORAGENICS INC
1990 Main Street, Suite 750
Sarasota FLORIDA 33634 US
CEO: Alan Joslyn
Employees: 4
Phone: 18132867900
ORAGENICS INC / OGEN FAQ
What does ORAGENICS INC do?
Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. The company is headquartered in Sarasota, Florida and currently employs 3 full-time employees. The company went IPO on 2003-07-09. The company is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The company is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.
Can you provide the latest stock price for ORAGENICS INC?
The current stock price of OGEN is 0.8587 USD. The price decreased by -0.13% in the last trading session.
Does OGEN stock pay dividends?
OGEN does not pay a dividend.
What is the ChartMill rating of ORAGENICS INC stock?
OGEN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the ownership details for OGEN stock?
You can find the ownership structure of ORAGENICS INC (OGEN) on the Ownership tab.
OGEN Technical Analysis
OGEN Financial Highlights
Over the last trailing twelve months OGEN reported a non-GAAP Earnings per Share(EPS) of -56.05. The EPS increased by 78.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -717.68% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OGEN Forecast & Estimates
7 analysts have analysed OGEN and the average price target is 2.04 USD. This implies a price increase of 137.57% is expected in the next year compared to the current price of 0.8587.